Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia - Wikidata - wikimedia - TriplyDB

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

http://www.wikidata.org/entity/Q34662889

about

The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents Iron therapy in anaemic adults without chronic kidney disease Erythropoietin or darbepoetin for patients with cancer Role of iron supplementation to erythropoiesis stimulating agents in the management of chemotherapy-induced anemia in cancer patients Safety and efficacy of intravenous iron therapy in reducing requirement for allogeneic blood transfusion: systematic review and meta-analysis of randomised clinical trials Pre-operative anaemia Prevalence and management of cancer-related anaemia, iron deficiency and the specific role of i.v. iron Iron deficiency in gastrointestinal oncology Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials.A European patient record study on diagnosis and treatment of chemotherapy-induced anaemia.The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study Iron metabolism and iron supplementation in cancer patients The role of intravenous iron in the treatment of anemia in cancer patients A double-blind, randomized, and active-controlled phase III study of Herbiron drink in the treatment of iron-deficiency anemia in premenopausal females in Taiwan.Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial.Iron deficiency in cancer patients.Perioperative anemia management in colorectal cancer patients: a pragmatic approach.Management of anemia in cancer patients.Diagnosis and management of anaemia of chronic disease: current status.Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials.Erythropoiesis-stimulating agents in cancer patients: reflections on safety.Targeting the hepcidin-ferroportin axis to develop new treatment strategies for anemia of chronic disease and anemia of inflammation.Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia - systematic review and meta-analysis of randomised controlled trials.Diagnosis and treatment of cancer-related anemia.Experimental and investigational therapies for chemotherapy-induced anemia.Effects of iron supplementation on erythropoietic response in patients with cancer-associated anemia treated by means of erythropoietic stimulating agents.Systematic review and meta-analysis of iron therapy in anaemic adults without chronic kidney disease: updated and abridged Cochrane review.Biosimilar epoetin zeta: extrapolation of indications and real world utilization experience.Use of biosimilar epoetin to increase hemoglobin levels in patients with chemotherapy-induced anemia: real-life clinical experience.Darbepoetin-alfa and intravenous iron administration after autologous hematopoietic stem cell transplantation: a prospective multicenter randomized trial.Potential health economic impact of intravenous iron supplementation to erythropoiesis-stimulating agent treatment in patients with cancer- or chemotherapy-induced anemia.Phase III randomized trial comparing intravenous to oral iron in patients with cancer-related iron deficiency anemia not on erythropoiesis stimulating agents.Chemotherapy-related anemia.A randomized comparison of once weekly epoetin alfa to extended schedule epoetin or darbepoetin in chemotherapy-associated anemia.A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors.Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis

P2860

Q24186166-1EC02776-B1A6-4E47-8494-1D346909F04B Q24187098-2D72233A-022E-4974-B69E-9A830777B841 Q24202335-CD7DB2CA-96B3-4447-B487-AE026F80F891 Q24203798-6FB2E2F1-E19A-4AA9-A217-D2163C43E6DE Q26829377-10816DA2-BBC4-492A-896E-0EDEA0E116CE Q26998362-97B802C3-1EC0-431C-87CF-F0253CB7AAB5 Q27004170-87A78A1A-8708-4A9D-8A63-51D273347DEA Q27023196-AFB8FA39-5929-419C-A77E-C18898B677CD Q31160832-38706108-BAD2-44D7-9ED0-648CA36C806A Q33848929-3BC7E5A4-0281-495F-837E-D992FDA47E79 Q34798132-401928C8-9503-4BCF-8684-61553381A6A6 Q36371665-01BA2574-F72D-49E4-922E-9971C5C27B34 Q36612686-06BE588B-757B-42DE-937D-5D9C5F98A04F Q37037816-2DF0B023-44DF-46FD-BE38-4E70651441B3 Q37355996-F864B814-23D1-466D-95DA-D9B1D05B4886 Q37429231-671C0AE4-266D-4E1A-86AD-27219A19F6B4 Q37602724-C89C8293-77EA-42CB-981A-48B946A4D68F Q37861195-18CC21EB-18B6-4EDA-ABA7-6C2CCC1994E0 Q37880158-E67348B8-FF78-4460-84EE-8A92834DA236 Q37942516-AAA60367-3E7F-47B9-828F-9F74561BCCE2 Q37960528-6A67A97D-6D4E-4C01-98EB-A70C26B34D6A Q37980044-371D5D13-C7F1-443D-B680-BD7B6E8CFD15 Q38033247-4D073E9F-2FC6-45A2-802A-3C8A3708DB27 Q38188501-8FA6F83B-3830-433C-BB3D-187920DAE496 Q38584639-E61DD858-B018-4FD7-8404-6FC336A5D897 Q38755414-D5BCD046-7C1C-4F7D-98C5-4EE971090743 Q38819226-36EB1C8D-795C-47F4-A70B-6FBAB9737875 Q38844794-2628CD1C-CD91-482E-B97A-4A035ED988CE Q39637230-C33C1E87-8ACE-436B-8C87-058927E6BEEA Q43667618-16ACE802-8699-478A-B9C2-D1FC3C2394E1 Q45802851-A99BE5FF-C48A-4FCB-8FEA-46E1188AA118 Q48164757-CAD43673-3B83-48AF-9548-DFFEBC3B90F3 Q48365358-0362F0A2-649B-4227-8E8D-CBFA04E7C25C Q50441089-C8A0AB6D-0897-4D7D-99E6-91E3CDA0792A Q51197806-B388E0D5-277F-491D-9ACD-5D77DD1E9F5E Q57191817-66ECA692-4ECB-4C7F-8865-20ECC8483A07 Q58908160-EA2F7D57-8CC9-4B10-9CAE-0B229865498E

P2860

Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia

http://www.wikidata.org/entity/Q34662889

description

2010 nî lūn-bûn

@nan

2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Phase III, randomized study of ...... chemotherapy-associated anemia

@ast

Phase III, randomized study of ...... chemotherapy-associated anemia

@en

Phase III, randomized study of ...... chemotherapy-associated anemia

@nl

type

label

Phase III, randomized study of ...... chemotherapy-associated anemia

@ast

Phase III, randomized study of ...... chemotherapy-associated anemia

@en

Phase III, randomized study of ...... chemotherapy-associated anemia

@nl

prefLabel

Phase III, randomized study of ...... chemotherapy-associated anemia

@ast

Phase III, randomized study of ...... chemotherapy-associated anemia

@en

Phase III, randomized study of ...... chemotherapy-associated anemia

@nl

P1433

Q34662889-73127CA4-6774-4C05-9962-9EB2C5A59AEE

P1476

Q34662889-C8F7A925-C878-4C9D-A81A-B2E82356BDA7

P2093

Q34662889-125C9DAB-E3E3-4AC2-A859-30EE0F607D2C

Q34662889-612A6501-EC98-45BC-869C-A8535B12CE80

Q34662889-67307F0B-1848-45F3-BF97-90C331712F66

Q34662889-6C4EDE72-1EA7-4CB4-A3C0-37CEAD8E1CEB

Q34662889-6EFC13C5-3511-49F7-AAA1-F0C319CFA168

Q34662889-72AAD24E-D9D1-43D7-AA4C-6A1D02450A01

Q34662889-9C5C0D1C-17E5-4278-BD6D-65B54047CFE7

Q34662889-A15E9C0A-2563-44AD-963C-A915B1F31711

Q34662889-BB5CD12D-2387-45D5-A225-414860C1E90E

P2860

Q34662889-09860251-DB90-44D1-B8E7-EAE8F8E0DEE3

Q34662889-171113A3-459A-4376-9B33-4A0C217895A8

Q34662889-17CAD078-1626-4642-A544-8D300ED80BFF

Q34662889-2784F1BB-2225-43DF-8FDB-9EF7B9407BBC

Q34662889-32B4A1B7-951D-44F7-AC0B-2917CA3C8AEF

Q34662889-604BE32E-8DB9-42AA-A454-B0195BF5B69E

Q34662889-6716A8E5-563E-4066-A8DB-45C03755A553

Q34662889-8918597F-0FFA-4060-AF91-E97AF479C09A

Q34662889-947163E8-F754-4B2B-BF37-08DDAEF6BDB8

Q34662889-9D745293-F61E-4F2E-AEA0-4308C09D7571

P304

Q34662889-E7BFA688-B4E8-4CAC-951F-9F8C193B448D

P31

Q34662889-FE27B6EE-C4E8-41DB-B900-0209C044CA22

P356

Q34662889-F0891697-A449-4F0B-A82D-07B94246DEF7

P407

Q34662889-CA62F860-8045-4259-892A-689BF99C4CC2

P433

Q34662889-5C4C5EBE-3571-4775-A794-57840B8C28DE

P478

Q34662889-07517C6F-0F3C-473D-B064-A17E9B9C9EF4

P50

Q34662889-49BC443F-BF85-4484-A1B8-C3A9CA5C761E

P577

Q34662889-EC993564-C3CC-4995-B747-D3C5F72F8321

P698

Q34662889-01385D02-7EA6-4EEA-9C1D-7B7379907F5B

P921

Q34662889-14318595-75BE-4B4A-AC78-A6305D6A1FA4

Q34662889-317BB66C-A27E-4F66-86C3-BA5F208DB8B4

Q34662889-E8DBC452-56D4-4E20-9320-CBAC75A78FB1

P932

Q34662889-0FAF3BFF-313D-420E-A568-1057B2104263

P356

JCO.2010.30.3644

P1433

Journal of Clinical Oncology

P1476

Phase III, randomized study of ...... chemotherapy-associated anemia

@en

P2093

Charles L Loprinzi

http://www.w3.org/2001/XMLSchema#string

Diane J Prager

http://www.w3.org/2001/XMLSchema#string

Jeff A Sloan

http://www.w3.org/2001/XMLSchema#string

Kendrith M Rowland

http://www.w3.org/2001/XMLSchema#string

Paul J Novotny

http://www.w3.org/2001/XMLSchema#string

Philip J Stella

http://www.w3.org/2001/XMLSchema#string

Robert Dalton

http://www.w3.org/2001/XMLSchema#string

Shaker R Dakhil

http://www.w3.org/2001/XMLSchema#string

Stephen P Kahanic

http://www.w3.org/2001/XMLSchema#string

P2860

September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents

Erythropoietin or Darbepoetin for patients with cancer

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update.

Anemia of chronic disease.

The role of intravenous iron in cancer-related anemia.

Assessing clinical significance in measuring oncology patient quality of life: introduction to the symposium, content overview, and definition of terms.

The anaemia of cancer: death by a thousand cuts.

Erythropoietin and iron-restricted erythropoiesis.

Intravenous iron in oncology.

Development of a symptom distress scale.

P304

97-105

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.30.3644

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

David P. Steensma

P577

2010-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21098317

http://www.w3.org/2001/XMLSchema#string

P921

Darbepoetin alfa

P932

3055863

http://www.w3.org/2001/XMLSchema#string